Jefferies Maintains Buy on BBIO BridgeBio Pharma, Inc. Feb 2026
Jefferies maintained its Buy rating on BridgeBio Pharma, Inc. (BBIO) on February 12, 2026, while raising the price target to $100 from $85. This BBIO analyst rating update makes the firm’s view more optimistic on valuation while keeping clinical and commercial risks in scope. We track how that change feeds through to investor positioning, current market reaction, and what it signals for next catalysts.
Continue Reading on Meyka
This article is available in full on our main platform. Get access to complete analysis, stock insights, and more.
Read Full Article →
